Recent Updates
Recently added Catalysts
LEGN Positive Sentiment

Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Key Takeaway: Legend Biotech will host a live webcast for investors during the 2025 ASCO Annual Meeting on June 1, 2025. CEO Ying Huang and CMO Mythili Koneru will present updates on the CARTITUDE development program. This event highlights Legend's commitment to advancing cancer treatment through innovative cell therapies.
Price reaction · baseline $27.78 (2025-05-16 close) · hit pre-market · 1 other LEGN headline(s) in the window, move may be shared
day 0 close · peak
+4.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Legend Biotech is hosting a significant investor event at ASCO 2025.
  • The event will feature expert clinicians discussing the CARTITUDE program.
  • The company is a leader in cell therapy, indicating strong market positioning.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+118%
120-day peak, hindsight
Typical move
18.4%
average across 6 past catalysts
Lead asset
LUCAR-DKS1 NK cells
Phase 1 · Relapsed/Refractory Autoimmune Diseases

Full Press Release Details

SOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, June 1, 2025, at 6:00 p.m. CT (7:00 p.m. ET) during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinicians as they review the latest updates from the CARTITUDE development program.
Investors and other interested parties may join the live webcast through thisweblinkor visit Legend Biotech’s website underEvents and Presentations.
About Legend BiotechWith over 2,600 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more atwww.legendbiotech.comand follow us onX (formerly Twitter)and LinkedIn.

INVESTOR CONTACT:Jessie YeungTel: (732) 956-8271jessie.yeung@legendbiotech.com

PRESS CONTACT:Mary Ann OndishTel: (914) 552-4625media@legendbiotech.com

Frequently Asked Questions

When is the Legend Biotech investor event?

The investor event is scheduled for June 1, 2025, at 6:00 p.m. CT.

Who will present at the investor event?

CEO Ying Huang and CMO Mythili Koneru will present at the event.

What will be discussed during the webcast?

The webcast will cover the latest updates from the CARTITUDE development program.

How can I join the investor webcast?

Investors can join the webcast through a provided link or Legend Biotech's website.

Last updated: May 19, 2025